吉西他滨化疗联合PD-1/PD-L1阻断治疗胰腺导管腺癌的研究进展  

Research Progress on Gemcitabine Chemotherapy Combined with PD-1/PD-L1 Inhibitors for Pancreatic Ductal Adenocarcinoma

作　　者：李立群 杨晓军[2,3] 全赢 侯孟森 赵永忠 LI Liqun;YANG Xiaojun;QUAN Ying;HOU Mengsen;ZHAO Yongzhong(The First Clinical School of Gansu University of Chinese Medicine,Lanzhou 730000,China;Gansu Provincial People's Hospital,Lanzhou 730000,China;Key Laboratory of Molecular Diagnosis and Precision Therapy of Surgical Tumors in Gansu Province,Gansu Provincial Engineering Research Center for Prevention and Control of Gastrointestinal Malignancies,Key Laboratory of Gastrointestinal Tumor Diagnosis and Treatment of National Health and Health Commission,Lanzhou730000,China)

机构地区：[1]甘肃中医药大学第一临床医学院,甘肃兰州730000 [2]甘肃省人民医院,甘肃兰州730000 [3]甘肃省外科肿瘤分子诊断与精准治疗重点实验室,甘肃省消化道恶性肿瘤防控工程研究中心,国家卫生健康委胃肠肿瘤诊治重点实验室,甘肃兰州730000

出　　处：《肿瘤学杂志》2023年第11期928-933,共6页Journal of Chinese Oncology

基　　金：甘肃省创新基地和人才项目资助(20JR10RA433);甘肃省省级科技计划重点研发项目(21YF5WA027);国家卫健委胃肠肿瘤诊治重点实验室2022年度硕博士/博士后基金项目(NHCDP2022001);甘肃省人民医院博士研究生导师培育项目(22GSSYA-3)。

摘　　要：胰腺导管腺癌(pancreatic ductal adenocarcinoma,PDAC)不仅对于PD-1/PD-L1阻断剂单药治疗无效,而且对于常用的吉西他滨化疗也产生了耐药性,原因可能是PDAC具有独特的肿瘤微环境。目前,已有相关研究报道吉西他滨加抗PD-1抗体治疗延长了PDAC肝转移小鼠模型的生存期。全文综述PDAC对吉西他滨治疗产生耐药性的机制,并且探讨了抗PD-1/PD-L1抗体联合吉西他滨治疗PDAC可改善患者生存期的可能性。Pancreatic ductal adenocarcinoma(PDAC)is usually resistant to PD-1/PD-L1 inhibitor monotherapy,as well as to gemcitabine chemotherapy,probably due to the unique tumor microenvironment of PDAC.Recent studies have shown that PD-1/PD-L1 inhibitors administrated with gemcitabine may prolong the survival of PDAC-bearing mice with liver metastasis,which brought new clue for clinical study.This paper reviews the mechanisms of PDAC resistant to PD-1/PD-L1 inhibitors and gemcitabine therapy,also explores the possibility of the combination of PD-1/PD-L1 inhibitors and gemcitabine for increasing treatment efficacy and improving survival of PDAC patients.

关 键 词：胰腺导管腺癌 肿瘤微环境 调节性T淋巴细胞 肿瘤相关巨噬细胞 免疫疗法 化学疗法 

分 类 号：R735.9[医药卫生—肿瘤]